Indications & Uses
LEQVIO is indicated for:
Pharmacology
Inclisiran is a double-stranded small interfering ribonucleic acid (siRNA). Its sense strand is attached to triantennary N-Acetylgalactosamine (GalNAc), which helps liver cells (hepatocytes) take it up. Once inside the hepatocytes, inclisiran uses the RNA interference mechanism and directs the catalytic breakdown of mRNA for PCSK9. That means more LDL-C receptors are recycled and more of them appear on the surface of the hepatocyte. The cell then takes up more LDL-C, and the level of LDL-C in the circulation falls.
Dosage Reference
Reference Information Only
Dosages shown are general references from official sources. Always consult your doctor or pharmacist for personalized dosing.
Adults:
The recommended dose of Inclisiran for adults and for children aged 12 years and older is 284 mg, given as a single subcutaneous injection. The first dose is followed by another at 3 months, and then one every 6 months.
If a planned dose is missed by less than 3 months, give Inclisiran and carry on with the patient's original schedule. If a planned dose is missed by more than 3 months, start again with a new schedule: give Inclisiran initially, again at 3 months, and then every 6 months.
Assess LDL-C when clinically indicated. The LDL-lowering effect of Inclisiran can be measured as early as 30 days after the first dose and at any time after that, whatever the timing of the dose.
Side Effects
In clinical trials with Inclisiran, the most common side effects, seen in 3% or more of people, were injection site reaction, arthralgia (joint pain) and bronchitis.
Cautions & Contraindications
Warnings & Precautions
Hypersensitivity reactions have been reported in patients treated with Inclisiran. Patients should be told what the signs and symptoms of a hypersensitivity reaction look like, and they should be advised to get medical attention promptly if any of them appear.
Pregnancy & Breastfeeding
Women who are pregnant, or who could become pregnant, should be told that Inclisiran may carry a risk to the fetus. If a patient knows or suspects she is pregnant, she should tell her doctor so they can decide together whether Inclisiran should be stopped.
Nothing is known about whether inclisiran passes into human milk, what it might do to a breastfed baby, or whether it affects milk production. In animal studies, inclisiran was found in the milk of lactating rats at every dose given.
⚠️ Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.
Storage
Store Inclisiran below 30°C, and keep it away from light and moisture. Keep it out of the reach of children.
Common questions about LEQVIO 284 mg/1.5 ml
What is LEQVIO 284 mg/1.5 ml SC Injection?
LEQVIO 284 mg/1.5 ml SC Injection is a medicine that contains Inclisiran. It is made by Nevian Lifescience PLC. It belongs to the Other Anti-anginal & Anti-ischaemic drugs group of medicines.
What is LEQVIO used for?
LEQVIO is used for: Hyperlipidemia.
What are the side effects of LEQVIO?
In clinical trials with Inclisiran, the most common side effects, seen in 3% or more of people, were injection site reaction, arthralgia (joint pain) and bronchitis.
Can I take LEQVIO during pregnancy or while breastfeeding?
Women who are pregnant, or who could become pregnant, should be told that Inclisiran may carry a risk to the fetus. If a patient knows or suspects she is pregnant, she should tell her doctor so they can decide together whether Inclisiran should be stopped. Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.
How should I store LEQVIO?
Store Inclisiran below 30°C, and keep it away from light and moisture. Keep it out of the reach of children.
Do I need a prescription for LEQVIO?
LEQVIO is a prescription (Rx) medicine. Take it as your doctor advises.